Salarius Pharmaceuticals regains full NASDAQ compliance

Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) announced it has regained compliance with all Nasdaq listing requirements after receiving notice on October 10, 2025, that it met the Equity Standard Requirement under Nasdaq Listing Rule 5550(b)(1).

The Houston-based biopharmaceutical company previously regained compliance with the Minimum Bid Price Requirement in September 2025. The company will be subject to a Mandatory Panel Monitor for one year from October 10, 2025.

"Salarius is now fully compliant with all Nasdaq listing requirements, marking another critical step in our planned merger with Decoy Therapeutics," said Mark J. Rosenblum, acting CEO and CFO of Salarius.

In January 2025, Salarius entered into a definitive merger agreement with Decoy Therapeutics Inc., a privately held preclinical biopharmaceutical company. Under the agreement, Decoy will merge with a wholly owned subsidiary of Salarius, with the combined entity to be named Decoy Therapeutics.

Decoy Therapeutics develops peptide conjugate therapeutics using its IMP3ACT platform and focuses on respiratory infectious diseases and gastroenterology oncology indications. The company expects to file an Investigational New Drug application with the FDA for its lead pan-coronavirus antiviral asset within the next 12 months.

Salarius operates as a clinical-stage biopharmaceutical company with two drug candidates for cancer patients. Its lead candidate, seclidemstat, is being studied in a Phase 1/2 clinical study at MD Anderson Cancer Center for myelodysplastic syndrome and chronic myelomonocytic leukemia.

You May Also Be Interested In

• Real and RE/MAX Holdings receive court approval for merger
• Solowin Holdings marks 10 years, expands into stablecoins and AI
• loanDepot receives NYSE non-compliance notice over stock price